

Genentech, Inc.

1 DNA WAY
South San Francisco, CA 94080
(650) 225-1000
Facsimile: (650) 952-9881

FACSIMILE TRANSMITTAL

DATE: October 31, 2002

Please deliver the following page(s) to:

NAME: David Romeo
Primary Examiner
Group Art Unit 1647
U.S. Patent and Trademark Office

FAX RECEIVED

NOV 01 2002

GROUP 1600

Fax No.: 703-872-9306

FROM: Janet E. Hasak *JEH*
Registration No.: 28,616

OFFICIAL

RE: U.S. Serial No.: 09/723,185
Our Docket No.: P1071P2C2

Number of Pages including this cover sheet - 9

CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 CFR § 1.8	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Janet E. Hasak	
Type or print name of person signing certification	
Signature <i>Janet E. Hasak</i>	Date: <i>10/31/02</i>

CONFIDENTIAL NOTE

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. The information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

If you do not receive all pages, please notify Janet Hasak at (650) 225-1896.

Enclosed for consideration and entry on the record in connection with the above application are: this cover page (1 page), an Amendment transmittal (1 page), and a Response to Restriction Requirement (7 pages).

Patent Docket P1071P2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Yvonne Man-yee Chen et al. Serial No.: 09/723,185 Filed: November 27, 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	Group Art Unit: 1647 Examiner: D. Romero CERTIFICATE OF FACSIMILE TRANSMISSION October 31, 2002 Date of Transmission I hereby certify that this correspondence, consisting of response to Restriction Requirement and Amendment Transmittal, is being facsimile transmitted to the Assistant Commissioner of Patents, Washington, D.C. 20231. <i>Janet E. Hasak</i> Janet E. Hasak
--	---

AMENDMENT TRANSMITTAL

Assistant Commissioner of Patents
 Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Fee Extra	Rate	Additional Fees
Total	25	-	51	0	18	\$0.00
Independent	2	-	4	0	80	\$0.00
___ Multiple dependent claim(s), if any					270	\$0.00
Total Fee Calculation						\$0.00

☒ No additional fee is required.

☐ The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$. A duplicate copy of this transmittal is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
 GENENTECH, INC.

Date: October 31, 2002

By: *Janet E. Hasak*
 Janet E. Hasak, Reg. No. 28,616
 Telephone N . (650) 225-1896



09157

PATENT TRADEMARK OFFICE

Patent Docket P1071P2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Chen et al. Serial No.: 09/723,185 Filed: 27 November 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	Group Art Unit: 1647 Examiner: David Romeo CERTIFICATE OF FACSIMILE TRANSMISSION October 31, 2002 Date of Transmission I hereby certify that this correspondence, consisting of Response to Restriction Requirement and Amendment Transmittal, is being facsimile transmitted to the Assistant Commissioner of Patents, Washington, D.C. 20231. Janet E. Hasak
--	---

9/c
 M.G.J
 11/12/02

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 1, 2002, please amend the above-identified application as follows.

IN THE CLAIMS:

Please add claims 52-57 as follows:

-
52. The peptide of claim 28 wherein Xaa₍₇₎ is Trp.
53. The peptide of claim 28 wherein Xaa₍₁₀₎ is Glu.
54. The peptide of claim 28 wherein Xaa₍₁₁₎ is Lys.
55. The peptide of claim 28 wherein Xaa₍₁₂₎ is Tyr.
56. The peptide of claim 28 wherein Xaa₍₁₃₎ is Phe.
57. The peptide of claim 28 wherein Xaa₍₇₎ is Trp, Xaa₍₁₀₎ is Glu, Xaa₍₁₁₎ is Lys, Xaa₍₁₂₎ is Tyr, and Xaa₍₁₃₎ is Phe.
-